Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Colchicine 0.6 mg Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

NCT02128490
View directory record Official record
Conditions
Gout, Moderate Renal Impairment
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
89
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 29, 2026, 2:32 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Revisiting the Mechanism of the Anti-inflammatory Effect of Colchicine

NCT04355585
View directory record Official record
Conditions
Colchicine Mechanism of Action
Interventions
Colchicine Tablets, Placebo oral tablet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anti-platelet Effects of Colchicine in Healthy Volunteers

NCT02140372
View directory record Official record
Conditions
Healthy
Interventions
Colchicine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

NCT02063997
View directory record Official record
Conditions
Gout
Interventions
Arhalofenate 600 mg, Allopurinol 300 mg, Colchicine 0.6 mg, Placebo, Arhalofenate 800 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
52
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Inflammation and Coronary Endothelial Function

NCT02366091
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Methotrexate, Colchicine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 29, 2026, 2:32 PM EDT
Recruiting Phase 4 Interventional

Colchicine in Acutely Decompensated HFREF

NCT06286423
View directory record Official record
Conditions
Heart Failure, Decompensated Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions
Colchicine 0.6 mg, Control/Placebo group
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout

NCT02330796
View directory record Official record
Conditions
Gout
Interventions
Bucillamine, Colchicine
Drug
Lead sponsor
Revive Therapeutics, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
San Roman, California • Arlington, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout

NCT02139046
View directory record Official record
Conditions
Gout
Interventions
Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
192
States / cities
Binghamton, Alabama • Birmingham, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

NCT01399008
View directory record Official record
Conditions
Gout
Interventions
Arhalofenate, Allopurinol, Colchicine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
16
States / cities
Lincoln, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Colchicine and CRP in Atrial Fibrillation and AF Ablation

NCT01755949
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Colchicine, 0.6 mg PO BID, Matching placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MPC-004 for the Treatment of an Acute Gout Flare

NCT00506883
View directory record Official record
Conditions
Gout
Interventions
High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
83
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol

NCT01451645
View directory record Official record
Conditions
Intercritical Gout
Interventions
Colchicine (Colcrys®), placebo, allopurinol
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Alabaster, Alabama • Mesa, Arizona • Upland, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Colchicine for the Treatment of Osteoarthritis of the Knee

NCT03913442
View directory record Official record
Conditions
Osteoarthritis, Osteo Arthritis Knee
Interventions
Colchicine 0.8 mg or 0.6 mg orally once daily, Placebo oral capsule
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome

NCT02153983
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Colchicine 0.6Mg Cap, Placebo capsules given, Colchicine 0.6Mg Tab
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 29, 2026, 2:32 PM EDT
Suspended Phase 4 Interventional Accepts healthy volunteers

Effect of Colchicine on Range of Motion After Manipulation Under Anesthesia for the Stiff Total Knee Replacement

NCT02926248
View directory record Official record
Conditions
Manipulation Under Anesthesia
Interventions
Colchicine, Placebo
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Impact of Colchicine and Low-dose Naltrexone on COVID-19

NCT04756128
View directory record Official record
Conditions
Covid19
Interventions
Colchicine 0.6 mg, Naltrexone
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Saint Louis Park, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability Study of Colcrys® Crushed and Sprinkled on Applesauce

NCT01130051
View directory record Official record
Conditions
Healthy
Interventions
Colchicine 0.6 mg tablet
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study Between Colchicine and Ketoconazole

NCT00983216
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Ketoconazole
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)

NCT04355143
View directory record Official record
Conditions
COVID-19
Interventions
Colchicine Tablets, Current care per UCLA treating physicians
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Early Phase 1 Interventional

Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease

NCT06212271
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Colchicine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice

NCT00984009
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Grapefruit Juice
Drug · Other
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2011 · Synced Sep 29, 2026, 2:32 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate the Safety of Colchicine

NCT05335148
View directory record Official record
Conditions
Radiation Therapy
Interventions
oral colchicine(0.6 mg) once a day
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Livingston, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 29, 2026, 2:32 PM EDT
Not listed Phase 3 Interventional

Use of Colchicine to Decrease Atrial Fibrillation Recurrence After Ablation

NCT05459974
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Colchicine 0.6 mg, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Sep 29, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Between Colchicine and Ritonavir

NCT00983515
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Ritonavir
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Sep 29, 2026, 2:32 PM EDT